Business Context and Reporting Period
This Form 6-K filing by Moolec Science SA, dated April 29, 2025, reports on corporate actions taken during April 2025. The Company, a foreign private issuer based in Luxembourg, announced the implementation of a reverse stock split following shareholder and board resolutions passed on April 22, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure adjustments.
- Share Consolidation Ratio: 1 new share for every 10 existing shares (10:1).
- Pre-Split Outstanding Shares: 40,126,840.
- Post-Split Outstanding Shares: Approximately 4,012,684.
- Par Value: Remains U.S.$0.01 per share.
- Fractional Shares: Rounded up to the nearest whole share; no fractional shares issued.
Material Changes
The primary material change is the reduction in the number of outstanding shares by approximately 90% effective May 14, 2025. This action is intended to increase the per-share trading price to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of U.S.$1.00 per share. The new shares will trade under CUSIP code L64875 120 on the Nasdaq Capital Market.
Outlook, Risks, and Management Commentary
Management states the reverse stock split is a compliance measure to maintain listing status on Nasdaq. The filing notes that, aside from fractional share adjustments, the split will not have a dilutive effect on shareholders. No specific financial guidance, risk factors, or contingencies beyond the listing compliance issue are detailed in this text.
Investor Verification Checklist
- Verify the effective date of the reverse stock split (May 14, 2025) and the start of trading for new shares.
- Confirm the updated CUSIP code (L64875 120) for trading purposes.
- Check the current market price to assess if the split successfully achieves the $1.00 minimum bid price requirement.
- Review the Company's Form 20-F for the most recent audited financial statements, as this filing contains no financial performance data.